Jump to content
Sign in to follow this  
Altostrata

Greden, 1993 Antidepressant maintenance medications: when to discontinue and how to stop

Recommended Posts

Altostrata

This paper reputedly recommends tapering over 6–12 months.

 

J Clin Psychiatry. 1993 Aug;54 Suppl:39-45; discussion 46-7.

Antidepressant maintenance medications: when to discontinue and how to stop.

Greden JF.

 

Source

 

Department of Psychiatry, University of Michigan Medical Center, Ann Arbor 48109-0704.

Abstract at http://www.ncbi.nlm.nih.gov/pubmed/8253705 Full text pdf https://drive.google.com/file/d/13JEjiREIZRg9YAfYViUqNrlsuaVQ6iJG/view?usp=sharing

 

Most depressive disorders, once developed, have a lifetime course. For the majority of patients, the risk for future episodes increases as the number of past episodes increases. The length of the well interval between episodes becomes progressively shorter with each new episode. Those who are older at onset often have higher probabilities of relapse during future years if not maintained on treatment. As the number of episodes grows larger and the patient becomes older, severity often intensifies, treatment responsivity to conventional antidepressants may diminish or even disappear, and the destructive consequences of the disorder progressively worsen. This destructive lifetime pattern can be prevented in many if not most patients since antidepressant and other maintenance medications are being shown to be efficacious in preventing most future episodes of depression, maintaining euthymia, and preserving quality of life. On the basis of these and other still-developing findings (and with the recognition that maintenance strategies have been inadequately tested in depressed children and adolescents), reasonable clinical wisdom might suggest that lifetime pharmacologic maintenance may be indicated for patients 50 years or older at first episode, 40 years or older with two or more prior episodes, or for those with three or more prior episodes. "Maintenance" dosages need to be comparable to established "treatment" dosages until it is proven that lower doses are efficacious; such data now are lacking. When medication is selected for long-term treatment, strong considerations should be given to the agent's side effect profile, since compliance is essential for success.(ABSTRACT TRUNCATED AT 250 WORDS)

 

Edited by Altostrata
added link to pdf

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this  

×